Document is current
Any future updates will be listed below
-
Authors
Zelba, Henning https://orcid.org/0000-0003-1391-0874
Shao, Borong
Rabsteyn, Armin https://orcid.org/0000-0002-0553-2693
Reinhardt, Annekathrin
Greve, Carsten
Oenning, Lisa
Kayser, Simone
Kyzirakos, Christina
Latzer, Pauline
Riedlinger, Tabea
Bartsch, Oliver
Wünsche, Julian
Harter, Johannes
Feldhahn, Magdalena
Bantel, Yannick
Johänning, Janina
Ködding, Jiri
Hadaschik, Dirk
Schulze, Martin
Battke, Florian
Maksimovic, Olga
Scheble, Veit
Miller, Alexandra M
Castro, Michael
Blumenthal, Deborah T
Glas, Martin
Reardon, David
Biskup, Saskia
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02454634 at ClinicalTrials.govnct02193347 at ClinicalTrials.govDocuments that mention this clinical trial
374 Discovery of mutant IDH1 reactive T cell receptors for transgenic T cell therapy
https://doi.org/10.1136/jitc-2023-sitc2023.0374
In-depth characterization of vaccine-induced neoantigen-specific T cells in patients with IDH1-mutant glioma undergoing personalized peptide vaccination
https://doi.org/10.1136/jitc-2024-011070
nct02771301 at ClinicalTrials.govDocuments that mention this clinical trial
In-depth characterization of vaccine-induced neoantigen-specific T cells in patients with IDH1-mutant glioma undergoing personalized peptide vaccination
https://doi.org/10.1136/jitc-2024-011070
Documents that mention this clinical trial
In-depth characterization of vaccine-induced neoantigen-specific T cells in patients with IDH1-mutant glioma undergoing personalized peptide vaccination
https://doi.org/10.1136/jitc-2024-011070
- License Information
